PE44995A1 - Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias - Google Patents

Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias

Info

Publication number
PE44995A1
PE44995A1 PE1995260142A PE26014295A PE44995A1 PE 44995 A1 PE44995 A1 PE 44995A1 PE 1995260142 A PE1995260142 A PE 1995260142A PE 26014295 A PE26014295 A PE 26014295A PE 44995 A1 PE44995 A1 PE 44995A1
Authority
PE
Peru
Prior art keywords
treatment
mometasone furoate
respiratory tract
lung diseases
day
Prior art date
Application number
PE1995260142A
Other languages
English (en)
Inventor
Imitiaz A Chaudry
Joel A Sequeira
Keith B Nolop
Mitchell Cayen
Nagamani Nagabhusan
James E Patrick
Francis M Cuss
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22692858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE44995(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE44995A1 publication Critical patent/PE44995A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A FUROATO DE MOMETASONA, UTIL COMO ANTIINFLAMATORIO, EN FORMA DE: 1) UNA SUSPENSION ACUOSA PARA EL TRATAMIENTO INTRANASAL, UNA VEZ AL DIA, DE LA RINITIS ALERGICA O DE LA RINITIS ESTACIONAL; 2) UN AEROSOL, QUE MEDIANTE LA INHALACION UNA VEZ POR DIA PUEDE SER UTIL EN EL TRATAMIENTO DEL ASMA; QUE TIENE COMO VENTAJA LA AUSENCIA TOTAL DE ABSORCION SISTEMICA, DISMINUYENDO LA POSIBILIDAD DE EFECTOS SECUNDARIOS SISTEMICOS
PE1995260142A 1994-01-27 1995-01-24 Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias PE44995A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18837294A 1994-01-27 1994-01-27

Publications (1)

Publication Number Publication Date
PE44995A1 true PE44995A1 (es) 1995-12-18

Family

ID=22692858

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995260142A PE44995A1 (es) 1994-01-27 1995-01-24 Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias

Country Status (29)

Country Link
EP (6) EP0740550B1 (es)
JP (6) JP3480736B2 (es)
KR (1) KR100234864B1 (es)
CN (4) CN101156860A (es)
AT (5) ATE525075T1 (es)
AU (1) AU691880B2 (es)
CA (1) CA2182086C (es)
CO (1) CO4340692A1 (es)
CY (2) CY2616B2 (es)
CZ (1) CZ219196A3 (es)
DE (1) DE69526425T2 (es)
DK (3) DK2156840T3 (es)
ES (3) ES2173947T3 (es)
FI (2) FI122395B (es)
HK (4) HK1040912A1 (es)
HU (1) HU227837B1 (es)
IL (1) IL112459A (es)
MX (1) MX9602246A (es)
MY (1) MY114665A (es)
NO (2) NO314535B1 (es)
NZ (1) NZ279979A (es)
PE (1) PE44995A1 (es)
PL (1) PL315575A1 (es)
PT (3) PT1174138E (es)
SG (1) SG47387A1 (es)
SK (1) SK283338B6 (es)
TW (1) TW329387B (es)
WO (1) WO1995020393A1 (es)
ZA (1) ZA95637B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5962445A (en) * 1996-05-09 1999-10-05 Amrad Operations Pty Ltd. Treatment of asthma and airway diseases
NZ334112A (en) * 1996-08-29 2000-07-28 Schering Corp Aerosol formulation comprising 1,1,1,2,3,3,3-heptafluoropropane, mometasone furoate and ethanol
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
CA2282360C (en) * 1997-03-20 2004-11-09 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
WO1999018971A1 (en) * 1997-10-09 1999-04-22 Schering Corporation Mometasone furoate suspensions for nebulization
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
JP2003511417A (ja) * 1999-10-08 2003-03-25 シェーリング コーポレイション 局所的鼻疾患治療
ECSP003747A (es) * 1999-11-02 2002-05-23 Smithkline Beecham Corp Metodo y composiciones para el tratamiento de las enfermedades pulmonares
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
WO2002011711A2 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
EP1344526B1 (en) 2000-12-22 2008-05-28 Nippon Shinyaku Co., Ltd. Preventives/remedies for inflammatory airway diseases
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
MXPA06003376A (es) * 2003-09-26 2006-06-08 Schering Corp Tratamiento de enfermedad pulmonar.
EP1680084A2 (en) * 2003-10-21 2006-07-19 Direct-Haler A/S A multiple route medication for the treatment of rhinitis and asthma
CA2543482A1 (en) * 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
SI1711164T1 (sl) * 2004-01-21 2010-06-30 Schering Corp Postopek za zdravljenje akutnega rinosinuzitisa
JP4893999B2 (ja) * 2004-10-22 2012-03-07 小野薬品工業株式会社 吸入用医薬組成物
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
RU2491074C2 (ru) 2007-11-13 2013-08-27 Меритедж Фарма, Инк. Кортикостероидные композиции
US20090123390A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
EP2309858A4 (en) 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP2328553B1 (en) * 2008-08-20 2020-06-10 The Regents of The University of California Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
EP2349206A2 (en) * 2008-10-10 2011-08-03 Schering Corporation Corticosteroid compositions and methods of treatments thereof
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
MY176808A (en) 2013-10-04 2020-08-21 Glenmark Pharmaceuticals Ltd Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN107260665B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种吸入用糠酸莫米松混悬液组合物
JP7391026B2 (ja) 2018-02-23 2023-12-04 グレンマーク・スペシャルティー・エスエー モメタゾン及びオロパタジンの組み合わせを用いた小児対象におけるアレルギー性鼻炎の治療
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN113933415B (zh) * 2021-09-30 2023-03-24 北京阳光德美医药科技有限公司 一种hplc-ms/ms测定人血浆中糠酸酯浓度的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4972830A (en) 1985-07-31 1990-11-27 Vortran Medical Technology, Inc. Inhalation device and method
US4873335A (en) 1986-03-12 1989-10-10 Schering Corporation 3-phenethyl-2-benzene-amides or aza-derivatives thereof
US4910192A (en) * 1987-12-04 1990-03-20 Sri International Topically active steroidal anti-inflammatory agents
EP0705614B1 (en) * 1989-04-28 2002-09-25 Riker Laboratories, Inc. Dry powder inhalation device
EP0965335B1 (en) * 1990-03-23 2003-09-17 Minnesota Mining And Manufacturing Company Metered-dose aerosol formulations
KR960013445B1 (ko) * 1990-09-10 1996-10-05 쉐링 코포레이션 모메타손 푸로에이트 모노하이드레이트 및 이의 제조방법
AU679165B2 (en) * 1990-10-16 1997-06-26 John Lezdey Treatment of inflammation
ATE114112T1 (de) * 1990-10-18 1994-12-15 Minnesota Mining & Mfg Aerosolzubereitung, die beclometason 17,21- dipropionat enthält.
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
ES2084360T3 (es) * 1991-06-10 1996-05-01 Schering Corp Formulaciones de aerosoles exentas de clorofluorocarbonos.
EP1736147A3 (en) * 1991-06-10 2007-10-17 Schering Corporation Non-chlorofluorocarbon aerosol formulations
SK279642B6 (sk) * 1991-06-26 1999-01-11 Schering Corporation Inhalátor na práškové látky
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
WO1993011745A1 (en) * 1991-12-12 1993-06-24 Glaxo Group Limited Medicaments
ATE171865T1 (de) * 1991-12-12 1998-10-15 Glaxo Group Ltd Arzneimittel
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
ATE145819T1 (de) * 1992-03-10 1996-12-15 Fisons Plc Inhalierbare arzneimittel
GB9207400D0 (en) * 1992-04-02 1992-05-13 Smithkline Beecham Plc Novel use
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias

Also Published As

Publication number Publication date
NO963132L (no) 1996-09-26
NZ279979A (en) 2001-03-30
EP0740550A1 (en) 1996-11-06
IL112459A (en) 1999-04-11
EP2156840A3 (en) 2010-05-19
CN1531967A (zh) 2004-09-29
CY2616B2 (en) 2012-05-23
NO328698B1 (no) 2010-04-26
JPH11286447A (ja) 1999-10-19
EP1174139B1 (en) 2011-09-21
NO20025002L (no) 1996-09-26
AU691880B2 (en) 1998-05-28
CO4340692A1 (es) 1996-07-30
JP5247265B2 (ja) 2013-07-24
CY2617B2 (en) 2012-05-23
SG47387A1 (en) 1998-04-17
HU9602043D0 (en) 1996-09-30
HU227837B1 (en) 2012-05-02
FI123580B (fi) 2013-07-31
EP1174138B1 (en) 2011-08-03
JP2008285497A (ja) 2008-11-27
HUT74884A (en) 1997-02-28
CN100441192C (zh) 2008-12-10
NO20025002D0 (no) 2002-10-17
EP1174139A3 (en) 2002-01-30
HK1040911A1 (en) 2002-06-28
JP2012036222A (ja) 2012-02-23
EP2156840A2 (en) 2010-02-24
PL315575A1 (en) 1996-11-12
PT740550E (pt) 2002-08-30
TW329387B (en) 1998-04-11
EP1201242B1 (en) 2011-11-02
HK1040918A1 (en) 2002-06-28
ATE518520T1 (de) 2011-08-15
NO963132D0 (no) 1996-07-26
DK1174138T3 (da) 2011-11-21
FI962828A0 (fi) 1996-07-12
IL112459A0 (en) 1995-03-30
DK0740550T3 (da) 2002-06-24
CA2182086C (en) 2000-04-11
DE69526425D1 (de) 2002-05-23
EP1174138A3 (en) 2002-01-30
EP1201242A2 (en) 2002-05-02
HK1135331A1 (en) 2010-06-04
JP2003313128A (ja) 2003-11-06
FI20115742L (fi) 2011-07-08
FI962828L (fi) 1996-07-12
JP2008031184A (ja) 2008-02-14
HK1040911B (en) 2011-11-18
ES2173947T3 (es) 2002-11-01
DE69526425T2 (de) 2002-12-05
EP1174139A2 (en) 2002-01-23
EP1174138A2 (en) 2002-01-23
ATE531364T1 (de) 2011-11-15
JPH09501700A (ja) 1997-02-18
ATE519489T1 (de) 2011-08-15
ATE525075T1 (de) 2011-10-15
CN101164542A (zh) 2008-04-23
ES2368827T3 (es) 2011-11-22
CZ219196A3 (en) 1996-12-11
JP3480736B2 (ja) 2003-12-22
NO314535B1 (no) 2003-04-07
CN101156860A (zh) 2008-04-09
HK1040912A1 (en) 2002-06-28
EP2156840B1 (en) 2011-08-10
ZA95637B (en) 1995-07-26
EP1192946A1 (en) 2002-04-03
CN1139384A (zh) 1997-01-01
EP0740550B1 (en) 2002-04-17
WO1995020393A1 (en) 1995-08-03
KR100234864B1 (ko) 1999-12-15
FI122395B (fi) 2011-12-30
SK82296A3 (en) 1997-03-05
AU1727195A (en) 1995-08-15
MY114665A (en) 2002-12-31
MX9602246A (es) 1997-07-31
PT2156840E (pt) 2011-10-18
ATE216243T1 (de) 2002-05-15
SK283338B6 (sk) 2003-06-03
CA2182086A1 (en) 1995-08-03
DK2156840T3 (da) 2011-11-21
EP1201242A3 (en) 2003-12-03
CN100358528C (zh) 2008-01-02
HK1041829A1 (en) 2002-07-26
ES2369516T3 (es) 2011-12-01
PT1174138E (pt) 2011-10-03

Similar Documents

Publication Publication Date Title
PE44995A1 (es) Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
CY1109030T1 (el) Συνθεση για εισπνοη
AR031348A1 (es) Inhalacion de oxido nitrico
UY28532A1 (es) Estimulador nasal
NO20083683L (no) Nebulisatorformulering
SE9900833D0 (sv) Novel combination
PE20020793A1 (es) Agente preventivo y/o terapeutico de enfermedades inflamatorias del tracto respiratorio
SE9900834D0 (sv) Novel combination
ES2093829T3 (es) Composicion farmaceutica para el tratamiento del asma y de las afecciones de las vias respiratorias.
WO2001007019A3 (en) Use of n-acetyl-cysteine in the treatment of allergic pathologies of the respiratory tract
TH51691A (th) วิธีการและสารผสมสำหรับการรักษาโรคปอด
UY27307A1 (es) Un inhibidor de pde4 y un agente anticolinérgico en combinación para tratar enfermedades obstructivas de vías respiratorias
ECSP034864A (es) Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias

Legal Events

Date Code Title Description
FD Application declared void or lapsed